Fidaxomicin: a new option for the treatment of Clostridium difficile infection.

@article{Johnson2012FidaxomicinAN,
  title={Fidaxomicin: a new option for the treatment of Clostridium difficile infection.},
  author={Alan P. Johnson and MarkH. Wilcox},
  journal={The Journal of antimicrobial chemotherapy},
  year={2012},
  volume={67 12},
  pages={
          2788-92
        }
}
The two drugs currently recommended for the treatment of Clostridium difficile infection (CDI), namely vancomycin and metronidazole, are both associated with high rates of recurrence of infection. Hence there is a need for new treatment options. The novel oral macrocyclic antibiotic fidaxomicin (previously known as PAR-101, OPT-80 and difimicin) was recently approved in the USA and in Europe for the treatment of CDI. Clinical trials have shown non-inferiority with regard to clinical cure when… CONTINUE READING
Tweets
This paper has been referenced on Twitter 7 times. VIEW TWEETS

Figures, Tables, and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 36 REFERENCES

Predictors of recurrent Clostridium difficile infection : implications for initial management

  • DW Eyre, D Wyllie, KE Dingle
  • 2011

Predictors of recurrent Clostridium difficile infection: implications for initial management. In: Abstracts of the Forty-ninth Conference of the Infectious Diseases

  • DW Eyre, D Wyllie, KE Dingle
  • 2011

Similar Papers

Loading similar papers…